Andrew Abrams

Andrew Abrams joined New Science Ventures as an Associate in September 2016 and became a Partner in July 2020. He was formerly an Associate in J.P. Morgan’s healthcare investment banking practice in London, where he focused on mergers and acquisitions and equity transactions in Europe and the U.S. He advised a wide array of clients spanning the biotechnology, pharmaceutical, medical device, diagnostic and service sub-sectors. Andrew serves on the Board of Directors for ProterixBio and formerly served on the Board of Directors of Paradigm Diagnostics (acquired by Exact Sciences in March 2020). He holds B.A., M.A. and M.Sci. degrees in Natural Sciences and Biochemistry from the University of Cambridge. He also holds an M.B.A. from Harvard Business School. Andrew was based in their New York office from 2016-2019 followed by a year in their San Diego therapeutics incubator. He is currently based in their London office.